Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 13/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15938356 | 1.00 | MAPK3 (0.51) | MAPK3TRPV1HDAC4HDAC6USP30 | |
| SCHEMBL25596033 | 0.89 | TRPV1 (0.49) | MAPK3TRPV1HDAC4HDAC6USP30 | |
| SCHEMBL22901094 | 0.88 | IDH1 (0.49) | MAPK3HDAC4USP30IDH1ULK1 | |
| SCHEMBL29821059 | 0.88 | IDH1 (0.49) | MAPK3HDAC4USP30IDH1ULK1 | |
| SCHEMBL15946703 | 0.87 | USP30 (0.46) | MAPK3TRPV1HDAC4HDAC6USP30 | |
| SCHEMBL29042588 | 0.86 | MAPK3 (0.55) | MAPK3BTKULK1 | |
| SCHEMBL21178194 | 0.86 | MAPK3 (0.55) | MAPK3BTKULK1 | |
| SCHEMBL17797711 | 0.85 | MAPK3 (0.49) | MAPK3TRPV1HDAC4HDAC6USP30 | |
| SCHEMBL22900801 | 0.85 | CDK4 (0.44) | MAPK3HDAC4HDAC6USP30IDH1 | |
| SCHEMBL29820639 | 0.85 | CDK4 (0.44) | MAPK3HDAC4HDAC6USP30IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | RECURSION PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| CN-118176189-A | Pyrimidine derivative, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| CN-117430598-A | Pyridone ring derivative, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| CN-116670123-A | Aromatic heterocyclic compound, pharmaceutical composition and application thereof | 湃隆生物科技有限公司（香港） | 2023-08-29 | — | — | CN | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK17, CDK8 | MAPK3 479/4885TRPV1 3559/4885HDAC4 279/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | MAPK3 2/4885TRPV1 4761/4885HDAC4 1995/4885 |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | CDK7, CDK17, CDK1 | MAPK3 522/4885TRPV1 1990/4885HDAC4 306/4885 |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | MAPK3 293/4885TRPV1 2814/4885HDAC4 749/4885 |
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK8, CDK6 | MAPK3 640/4885TRPV1 4140/4885HDAC4 186/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MAPK3 3/4885TRPV1 3780/4885HDAC4 1130/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MAPK3 3/4885TRPV1 3780/4885HDAC4 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.